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In light of their closely related mechanisms of action, and preliminary clinical evidence suggesting that they possess similar
efficacies, it has been anecdotally suggested that vigabatrin and tiagabine may prove to be therapeutically indistinguishable.
As a result, we have conducted a preclinical comparison of their anticonvulsant profile and mechanism of action. Pentylenete-
trazol and maximal electroshock seizures were employed to determine the experimental anticonvulsant profile. Mechanisms
of action were investigated using assays of γ -aminobutyric acid (GABA), GABA-transaminase and glutamic acid decarboxy-
lase in mouse brain and GABA uptake and GABA-transaminase in rat astrocyte cultures. Vigabatrin was without effect on
either pentylenetetrazol- or maximal electroshock-induced seizures, whereas tiagabine increased the latency to pentylenetetra-
zol seizures and reduced the incidence of maximal electroshock seizures. In mouse brain assays, tiagabine was without effect,
while vigabatrin increased GABA concentrations and reduced GABA-transaminase and glutamic acid decarboxylase activi-
ties. In cortical astrocyte cultures, vigabatrin reduced the activities of both GABA uptake and GABA-transaminase, whereas
tiagabine blocked GABA uptake alone. These results suggest that vigabatrin and tiagabine have differing efficacy in experimen-
tal seizure models and distinct neurochemical effects. It is possible, then, that these drugs will have different spectra of activity
and toxicity profiles in human epilepsy.
c© 1999 BEA Trading Ltd
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In the 10–15 year period leading up to 1989, there
was a hiatus in the introduction of novel therapies for
epilepsy. Since then, however, eight new antiepileptic
drugs have reached the global market-place1. These
new generation pharmaceuticals represent the first
fruits of an intensive rational drug design and devel-
opment programme aimed at addressing the signifi-
cant clinical problem of refractory epilepsy2, 3. Much
of these efforts have been targeted towards the investi-
gation of glutamate and γ -aminobutyric acid (GABA)
as the principal excitatory and inhibitory neurotrans-
mitters, respectively, in the mammalian brain4, 5.
Potentiation of GABA is regarded as one of the most
attractive mechanisms of action for novel antiepileptic
agents and can be achieved by increased synthesis or
release, receptor-dependent modulation, or reduced in-
activation of this important neurotransmitter6. GABA
∗ E-mail: g.j.sills@clinmed.gla.ac.uk1059–1311/99/070404 + 08 $12.00/0inactivation is a two-step process, initially involving
a specific sodium- and energy-dependent cellular up-
take7 and culminating in a mitochondrial metabolism
catalysed by the enzyme GABA-transaminase8. Viga-
batrin and tiagabine are two of the new generation of
antiepileptic drugs9, both of which are believed to ex-
ert their pharmacological effects via single and spe-
cific actions on GABA inactivation10, 11.
Vigabatrin is an ethyl analogue of GABA and has
been proposed to work by an irreversible inhibition
of GABA-transaminase12–14. In contrast, tiagabine is
a nipecotic acid derivative which is believed to act
by blockade of GABA uptake into neurones and glial
cells15, 16. Inhibition of GABA-transaminase results in
an increase in whole brain GABA concentration17, 18
whereas blockade of GABA uptake temporarily sus-
tains levels of endogenously released GABA in the
synapse16. Clinically, both drugs appear to have par-
ticular efficacy against partial seizures with or without
secondary generalization19, 20.c© 1999 BEA Trading Ltd
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tion as their mechanisms of action and similar clini-
cal efficacies, it can be suggested that vigabatrin and
tiagabine may prove to be therapeutically indistin-
guishable. The aims of the following studies, there-
fore, were to compare and contrast the experimen-
tal anticonvulsant profiles and mechanisms of action
of these two new GABAergic antiepileptic agents us-
ing the traditional pentylenetetrazol and maximal elec-
troshock seizure tests and a battery of GABA-related
neurochemical assays in mouse cortex and primary rat
astrocyte cultures.
MATERIALS AND METHODS
Vigabatrin (D,L-4-aminohex-5-enoic acid) and
tiagabine ((R-)-(-)-1-[4,4-Bis(3-methyl-2-thienyl)-3-
butenyl]-3-piperidine-carboxylic acid, hydrochloride)
were kind gifts from Marion Merrell Dow (Win-
nersh, UK) and Novo Nordisk A/S (Bagsvaerd,
Denmark) respectively. Radiolabelled GABA (γ -
[14C(U)]-aminobutyric acid) was obtained from NEN
Research Products (Stevenage, UK). Cell culture
grade Dulbecco’s modified Eagle medium, horse
serum, L-glutamine, penicillin and streptomycin were
obtained from Gibco BRL (Paisley, UK). All other
chemicals (reagent grade) were obtained from the
Sigma Chemical Company (Poole, UK) and solvents
were purchased from Rathburn Chemicals (Walker-
burn, UK).
Whole animal studies were performed in groups of
adult, male ICR mice (25–30 g; Harlan Olac, Bicester,
UK), housed in a controlled temperature/humidity en-
vironment with a 12 hour day/night cycle and allowed
access to food and water ad libitum. Cell culture stud-
ies were performed in primary cultures of rat cortical
astrocytes isolated and maintained by the methods de-
scribed by Leach and colleagues21. All experimental
work was governed by the Animals (Scientific Proce-
dures) Act, 1986 (UK).
Pentylenetetrazol-induced seizures
Pentylenetetrazol seizures were induced in accordance
with the method described by Lo¨scher and Schmidt22.
Pentylenetetrazol was administered subcutaneously in
the back of the neck in a dose of 85 mg/kg in
0.9% saline. The latency to the first observed gen-
eralized seizure with loss of the righting reflex was
recorded.Electroshock-induced seizures
Electroshock seizures were induced in accor-
dance with the methods described by Lo¨scher and
Schmidt22. Constant current electroshock stimuli were
delivered via auricular electrodes from a Ugo Basile
7800 ECT unit (Comerio, Italy). Electrodes were
moistened with 0.9% saline to improve conductance.
Maximal electroshock stimuli consisted of 0.2 sec-
onds of rectangular positive pulses (50 mA at 60 Hz,
pulse width = 0.4 ms) to induce tonic hind-limb ex-
tension in control animals. The percentage of animals
exhibiting tonic hind-limb extension in each treatment
group was recorded.
Neurochemical assays
Cortical GABA concentrations, protein concentrations
and the activities of GABA-transaminase and glutamic
acid decarboxylase were determined as previously de-
scribed23.
GABA uptake and GABA-transaminase activity
in astrocyte cultures
GABA uptake studies were performed by the meth-
ods described by Leach and colleagues21. The tech-
niques used in the analysis of GABA-transaminase in
astrocyte cultures were a modification of those em-
ployed for the analysis of GABA uptake21 and those
described for the whole brain GABA-transaminase as-
say by Sills and colleagues23. Briefly, cultures were
prepared and exposed to the appropriate drug concen-
trations as described for the GABA uptake studies21,
with the exception of a 3 ml volume being employed
for the final one hour drug exposure period. At the end
of the drug exposure period, the cultures were washed
immediately with five volumes (2 ml) of balanced salt
solution (BSS) and the cells removed from the plates
in 1 ml ice-cold ethylene diamine tetra-acetic acid
buffer (see Ref.23 for composition). Thereafter the en-
zyme assay was performed as previously described23
although protein concentrations of individual cell cul-
ture samples were adjusted to 0.2 mg/ml prior to assay
as opposed to 1 mg/ml for whole brain samples.
Experimental protocol
Effects of vigabatrin and tiagabine on
pentylenetetrazol-induced seizures
Sixty adult male ICR mice (25–30 g) were random-
ized into five groups (n = 12/group) and vigaba-
trin was administered intraperitoneally in doses of
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administration (Fig. 1b).25, 50, 100 and 200 mg/kg. The fifth group (con-
trol) received vehicle (0.9% saline) alone. Another
60 adult male ICR mice were also randomized into
five groups (n = 12/group) and tiagabine was ad-
ministered intraperitoneally in doses of 0.5, 1, 2 and
5 mg/kg. Again, the fifth group (control) received ve-
hicle (0.9% saline) alone. At 6 hours (tiagabine) and
24 hours (vigabatrin) post-administration, six animals
from each group were subjected to pentylenetetrazol-
induced seizures as described above. The remaining
six animals in each group continued to receive the ap-
propriate control/drug treatment once daily for eight
days. At 6 hours (tiagabine) and 24 hours (vigabatrin)
after drug administration on the eighth day, the re-
maining animals were subjected to pentylenetetrazol-
induced seizures as described above.
Effects of vigabatrin and tiagabine on maximal
electroshock-induced seizures
One hundred adult male ICR mice (25–30 g) were
randomized into five groups (n = 20/group) and vi-
gabatrin was administered intraperitoneally in doses
of 25, 50, 100 and 200 mg/kg. The fifth group (con-
trol) received vehicle (0.9% saline) alone. Another
100 adult male ICR mice were also randomized into
five groups (n = 20/group) and tiagabine was ad-
ministered intraperitoneally in doses of 0.5, 1, 2 and
5 mg/kg. Again, the fifth group (control) received
vehicle (0.9% saline) alone. At 6 hours (tiagabine)
and 24 hours (vigabatrin) post-administration, 10 an-
imals from each group were subjected to maximal
electroshock-induced seizures as described above. The
remaining 10 animals in each group continued to re-
ceive the appropriate control/drug treatment once daily
for eight days. At 6 hours (tiagabine) and 24 hours
(vigabatrin) after drug administration on the eighth
day, the remaining animals were subjected to maximal
electroshock-induced seizures as described above.
Effects of vigabatrin and tiagabine on GABA-related
neurochemistry in mouse cortex
Adult male ICR mice were randomized into seven
groups (n = 18/group) and administered vigaba-
trin (10, 50 and 250 mg/kg) or tiagabine (0.4, 2 and
10 mg/kg) intraperitoneally. The seventh group (con-
trol) received vehicle (0.9% saline) alone. Treatment
was continued once daily for eight days. At 6 hours af-
ter the final dose, the animals were sacrificed and their
brains removed. The cerebral cortices were dissected
free and the samples were stored at −70 ◦C until re-
quired for assay. Six cortices from each group were
employed in the investigation of GABA concentration,
GABA-transaminase activity and glutamic acid decar-
boxylase activity.Effects of vigabatrin and tiagabine on GABA-related
neurochemistry in rat astrocyte cultures
Fully matured rat cortical astrocyte cultures were ran-
domized into seven groups (n = 20/group) and ex-
posed to 10, 50, 100, 250, 500 and 1000 µM vigaba-
trin. The seventh group (control) was exposed to vehi-
cle (BSS) alone. Following a one-hour incubation pe-
riod, 10 cultures from each group were analysed for
GABA uptake activity and the remaining 10 cultures
were analysed for GABA-transaminase activity. This
experiment was repeated using a further batch of rat
astrocyte cultures exposed to 0, 10, 50, 100, 250, 500
and 1000 nM tiagabine for a period of one hour.
Statistical analysis
Statistical analysis was performed using MINITAB
for Windows statistical package (Version 10.1) on
a Viglen 4DX266 microcomputer. Pentylenetetrazol
seizure latencies were expressed as absolute values
and compared with control by one-way analysis of
variance with Dunnett correction for multiple com-
parisons. Maximal electroshock seizure data were also
expressed as absolute values and compared with con-
trol using Fisher’s exact test, with a Bonferroni correc-
tion for multiple comparisons. GABA concentrations
and the activities of GABA-transaminase, glutamic
acid decarboxylase and GABA uptake were calculated
as the percentage of mean control values. Group re-
sults were then expressed as mean percentages ± the
standard error of the mean (SEM) and compared with
control by one-way analysis of variance with a Dun-
nett correction for multiple comparisons.
RESULTS
Effects of vigabatrin and tiagabine on
pentylenetetrazol-induced seizures
Single dose and repeated treatments with vigabatrin
(25–200 mg/kg) were without effect on the latency
to the first generalized seizure induced by 85 mg/kg
pentylenetetrazol at 24 hours post-administration
(Fig. 1a). In contrast, acute (2 and 5 mg/kg) and
chronic (1 mg/kg) treatment with tiagabine signif-
icantly increased the time to the first generalized
seizure induced by pentylenetetrazol at 6 hours post-
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Fig. 1: Effect of (a) vigabatrin (0–200 mg/kg) and (b) tiagabine (0–5 mg/kg) on the latency to the first generalized seizure induced
by pentylenetetrazol (85 mg/kg) at 24 hours (vigabatrin) and 6 hours (tiagabine) post-administration in adult male mice. Single
dose treatment is denoted by the solid bars and repeated treatment by the hatched bars. Results (n = 6) are expressed as the
mean of absolute values and error bars denote the standard error of the mean. Statistical significance (∗P < 0.05) was
determined by one-way analysis of variance with Dunnett correction.Effects of vigabatrin and tiagabine on maximal
electroshock-induced seizures
Single-dose vigabatrin treatment (25–200 mg/kg) was
without effect on the incidence of tonic seizures in-
duced by maximal electroshock at 24 hours post-
administration (Fig. 2a). Repeated treatment with
50 mg/kg vigabatrin significantly reduced the inci-
dence of tonic seizures induced by maximal elec-
troshock at 24 hours after the final dose (Fig. 2a), al-
though all other doses were without effect. Again, in
contrast, acute and chronic treatment with tiagabine
(2 and 5 mg/kg) significantly reduced the incidence
of tonic seizures induced by maximal electroshock at
6 hours post-administration (Fig. 2b).
Effects of vigabatrin and tiagabine on GABA-related
neurochemistry in mouse cortex
Repeated treatment with vigabatrin (50 and
250 mg/kg) significantly increased cortical GABA
concentration and reduced the activities of GABA-
transaminase and glutamic acid decarboxylase at
6 hours after the final dose (Fig. 3a). Repeated treat-
ments with tiagabine (0.4–10 mg/kg) were essen-
tially without effect on any of the parameters inves-
tigated, although 2 mg/kg tiagabine significantly in-
creased the activity of GABA-transaminase at 6 hours
post-administration (Fig. 3b). Mean control values
(±SEM) for GABA concentration and the activities
of GABA-transaminase and glutamic acid decarboxy-
lase were 265.5(±16.6) µg/g, 861.4(±65.8) pmol/mg
protein/min and 2.26(±0.19) nmol/mg protein/min,
respectively.Effects of vigabatrin and tiagabine on GABA-related
neurochemistry in rat astrocyte cultures
A one-hour exposure to vigabatrin (10–1000 µM) re-
duced the activity of GABA-transaminase in primary
cultures of rat cortical astrocytes in a dose-dependent
manner and also significantly reduced GABA up-
take into these cells (Fig. 4a). A one-hour expo-
sure to tiagabine (10–1000 nM) was without effect
on GABA-transaminase activity but significantly re-
duced GABA uptake (Fig. 4b). Mean control values
(±SEM) for GABA-transaminase activity and GABA
uptake were 490.4(±35.8) pmol/mg protein/min and
383.9(±35.9) pmol/mg protein/min, respectively.
DISCUSSION
Vigabatrin and tiagabine are new antiepileptic agents
with closely related pharmacological actions on
GABA inactivation and similar clinical efficacies.
The recent preliminary observation24 that tiagabine
monotherapy may have detrimental effects on visual
field perimetry in epileptic patients, in a manner sim-
ilar to that reported for vigabatrin25–28, has fuelled
speculation that these drugs may prove to be clini-
cally indistinguishable. In light of this observation,
and other such anecdotal reports, the aims of these
studies were to compare and contrast vigabatrin and
tiagabine in terms of their experimental anticonvulsant
profiles and mechanisms of action using the traditional
pentylenetetrazol and maximal electroshock tests in
mice and a range of GABA-related neurochemical as-
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Fig. 2: Effect of (a) vigabatrin (0–200 mg/kg) and (b) tiagabine (0–5 mg/kg) on the incidence of tonic hind-limb extension (THE)
induced by maximal electroshock (50 mA; 0.2 s) at 24 hours (vigabatrin) and 6 hours (tiagabine) post-administration in adult
male mice. Single-dose treatment is denoted by the solid bars and repeated treatment by the hatched bars. Results (n = 10) are
expressed as the percentage of animals within each group exhibiting generalized tonic seizures. Statistical significance
(∗P < 0.05) was determined by Fisher’s exact test with Bonferroni correction.
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Fig. 3: Effect of (a) vigabatrin (0–250 mg/kg) and (b) tiagabine (0–10 mg/kg) on the concentration of GABA (open circles) and
the activities of GABA-transaminase (open triangles) and glutamic acid decarboxylase (open squares) in mouse cortex at
6 hours after repeated (once daily for 8 days) administration. Results (n = 6) are expressed as the mean percentage of mean
control values. Standard errors (SEM) were ≤ 10% throughout. Error bars have been omitted for ease of comprehension.
Statistical significance (∗P < 0.05) was determined by one-way analysis of variance with Dunnett correction.says in mouse cortex and primary rat astrocyte cul-
tures.
There is a reasonable body of evidence regard-
ing the effects of vigabatrin and tiagabine on ex-
perimental seizures induced by the systemic ad-
ministration of chemoconvulsant compounds. Both
drugs are active against seizures induced by the β-
carboline compound methyl-6,7-dimethoxy-4-ethyl-
β-carboline-3-carboxylate29–31 whereas it would ap-
pear that vigabatrin alone has activity in bicuculline
and picrotoxin models32–34. In the above studies, viga-
batrin was without effect on pentylenetetrazol-induced
seizures, following both single and repeated adminis-tration. In contrast, specific doses of tiagabine signif-
icantly increased the seizure latency. Although the ef-
ficacy of tiagabine in the pentylenetetrazol test is well
established30, 31, there is a degree of conflict regard-
ing the action of vigabatrin in this model. There is
some evidence to suggest that the drug is active against
pentylenetetrazol-induced seizures33, 35, 36, but there
are a similar number of reports to the contrary31, 34, 37.
On close inspection, it would appear that species and
strain differences play a part in this experimental dis-
crepancy, that drug incubation times also influence
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Fig. 4: Effect of (a) vigabatrin (0–1000 µM) and (b) tiagabine (0–1000 nM) on the activities of GABA-transaminase (open circles)
and GABA uptake (open squares) in primary cultures of rat cortical astrocytes following a one-hour exposure. Results (n = 8) are
expressed as the mean percentage of mean control values and error bars denote the standard error of the mean. Statistical
significance (∗P < 0.05) was determined by one-way analysis of variance with Dunnett correction.the results and that an anticonvulsant effect is gen-
erally only observed when the dose of vigabatrin is
high and that of pentylenetetrazol is moderate to low.
Thus, it would appear that tiagabine is effective in the
traditional pentylenetetrazol test, while the activity of
vigabatrin remains open to debate. In terms of anti-
convulsant profiles against chemoconvulsant-induced
seizures, the two drugs are clearly different.
Of the experimental seizure models which require
electrical induction, the kindling and maximal elec-
troshock models are most widely employed and re-
ported. In amygdaloid kindling, both vigabatrin38–40
and tiagabine41 have demonstrated efficacy although
it has been suggested that vigabatrin is only effec-
tive against generalized seizures in this model, while
tiagabine has activity against the focal seizure com-
ponent also31. In the maximal electroshock stud-
ies described herein, vigabatrin was essentially with-
out effect, despite an unexplained action following
repeated administration of 50 mg/kg of the drug.
In contrast, single and repeated administration with
higher doses of tiagabine elicited a significant an-
ticonvulsant response. These effects, or indeed lack
of them, are again not entirely consistent with pre-
viously published data. There is some evidence to
suggest that vigabatrin is active against maximal
electroshock-induced seizures42, 43 but generally only
following direct micro-injection of the drug into dis-
crete brain regions. It is more widely reported that
systemically administered vigabatrin is inactive in this
model22, 33, 34, 44. Tiagabine has also been reported to
be essentially devoid of activity in the maximal elec-
troshock test, although it does appear to have some de-
gree of efficacy at very high dose after a 30-minutepre-treatment period30, 31. It is possible, although un-
likely with such a short-acting compound45, that the
anticonvulsant effect of tiagabine in this model is only
manifested after a long incubation period, such as the
six-hour interval used in this study. Thus, it is un-
clear whether tiagabine has any activity in the tradi-
tional maximal electroshock test, whereas vigabatrin
is almost certainly without effect. Although the dis-
tinction between the drugs is not as clear cut as with
the chemoconvulsant-induced seizures, proposed dif-
ferences in their efficacy against kindled seizures and
potential differences in the maximal electroshock test
would suggest that vigabatrin and tiagabine have dif-
fering actions in experimental seizure models which
rely on electrical induction.
It is well recognized that the mechanisms of action
of vigabatrin and tiagabine are similar, in that they
have both been reported to exert their pharmacological
effects by an inhibition of GABA inactivation31. Al-
though mitochondrial GABA metabolism and cellular
GABA uptake are clearly separate biochemical phe-
nomena, they are inextricably linked in a physiological
sense. It is likely that the temptation to view these two
processes collectively has fuelled the speculation of
vigabatrin and tiagabine being clinically indistinguish-
able. The above ex vivo studies have, however, empha-
sized the clear pharmacological differences between
the drugs. Tiagabine was essentially without effect on
any of the parameters investigated, although a small,
unexplained increase in GABA-transaminase activity
was observed following repeated administration of a
moderate dose of the drug. In contrast, vigabatrin sig-
nificantly reduced the activity of GABA-transaminase
and, as a result, effected a large increase in cortical
410 G. J. Sills et al.
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tivity of glutamic acid decarboxylase. These actions
of vigabatrin have been observed previously46–48 and
were explained by an effect of the drug on its target
enzyme GABA-transaminase, leading to an increase
in GABA levels and a resultant decrease in glutamic
acid decarboxylase activity by a negative feedback
mechanism. Other authors have, however, proposed
that vigabatrin has a direct inhibitory effect on glu-
tamic acid decarboxylase following repeated admin-
istration17. With the methods employed here, it was
not possible to ascertain which of these explanations
was responsible for the observed inhibition of glu-
tamic acid decarboxylase. These studies have, how-
ever, served to highlight the important pharmacolog-
ical distinction between vigabatrin and tiagabine.
The final investigations also considered the mecha-
nisms of action of vigabatrin and tiagabine, comparing
their effects on the uptake and metabolism of GABA
in primary cultures of rat cortical astrocytes. A one-
hour exposure to vigabatrin significantly reduced the
uptake of GABA into these cells and effected a dose-
dependent inhibition of its mitochondrial metabolism
by GABA-transaminase. By comparison, tiagabine re-
duced GABA uptake alone. The inhibitory effects of
vigabatrin on GABA-transaminase, and tiagabine on
GABA uptake, confirm previous reports on their re-
spective mechanisms of action12, 13, 15, 16. In contrast,
the effect of vigabatrin on GABA uptake is not widely
recognized. Although these findings support the pre-
liminary observations of Leach and co-workers21, they
contradict those of Schousboe and colleagues49. It
is possible that the use of mixed glial cell cultures,
as opposed to a single cell type culture, may be the
confounding factor, with the glial cell composition50
likely to vary widely between laboratories. Whatever
the basis of the discrepancy, if this striking effect of
vigabatrin is substantiated in further studies, then an
inhibition of GABA uptake would represent an impor-
tant secondary mechanism of action of the drug and
one which could help to explain a variety of anoma-
lies associated with its use in the laboratory21 and the
observation of rebound seizures upon its clinical with-
drawal51.
In conclusion, the results of these investigations sug-
gest that, in spite of anecdotal reports regarding sim-
ilarities between vigabatrin and tiagabine, there are
clear differences between the drugs in terms of their
activities in experimental seizure models. In addi-
tion, neurochemical investigations have confirmed the
widely reported, and clearly distinct, principal mecha-
nisms of action of the two drugs, but have also uncov-
ered a potentially important, secondary mechanism of
vigabatrin action which it may share with tiagabine.
There is, therefore, ample evidence, both herein and
in the literature, to suggest that the two compoundsare sufficiently different, particularly in terms of their
activities in experimental seizure models and in their
principal mechanisms of action, to assume that they
will have different spectra of activity and toxicity in
human epilepsy.
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